Drug Survival of Hidradenitis Suppurativa Patients Treated with Infliximab, Adalimumab

These findings from AAD 2024 did not include statistically significant infliximab response predictors, though it had been the largest reported cohort on the subject to date.

Related Keywords

California ,United States ,San Diego ,American ,Linkedin Albert Young ,Young ,Henry Ford Health System ,American Academy Of Dermatology ,Kalbert Young ,Hurley Stage ,Annual Meeting ,Henry Ford Health ,